New Medications
Resource Center
Featured
07/27/2026
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
07/27/2026
07/23/2026
Anthony Calabro, MA
The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.
07/23/2026
07/21/2026
Anthony Calabro, MA
The FDA expanded approval of exagamglogene autotemcel (Casgevy) for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.
...
07/21/2026
Interactive Features
08/13/2016
Joshua is an 80-year-old man who had been stable on coumadin for 12 months, consistently demonstrating an INR of 2.2 to 3.1. Today, Joshua presented with an INR of 21.4, which results in immediate admission...
08/13/2016
Oral and Perioral Lesions
Oral and Perioral Lesions
03/03/2016
We previously met Zeke, a 19-year-old college student with a history of recurrent aphthous ulcers.
03/03/2016
11/22/2015
Researchers recently investigated inebilizumab as a potential treatment option for patients with immunoglobulin G4-related disease. Test your understanding of the findings!
11/22/2015
09/22/2014
We previously met Louis, a healthy 68-year-old male who currently takes no medications but has been reluctant to start statin use due to concerns that it may cause dementia. Today, you receive a call from...
09/22/2014
Clinical Insights
09/12/2020
In this 7-minute video, Dr Hudesman recaps his presentation on new and emerging therapeutic targets in IBD.
09/12/2020
Inflammatory Bowel Disease
Inflammatory Bowel Disease
07/25/2020
David Rubin, MD, review his talk at the virtual AIBD 2020 regional meeting July 25 on new and emerging therapeutics for inflammatory bowel disease.
07/25/2020
07/15/2020
He discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD.
07/15/2020
03/08/2015
In this article Michael J. Bloch, MD, writes about the potential use of a polypill for cardiovascular disease prevention and discusses how the results of recent research supports the potential use in the...
03/08/2015
